Rowpar Pharmaceuticals – FDA Warning Letter, Dec 7, 2020
On December 18, 2020, the FDA and FTC issued a Warning Letter to the company operating www.closys.com, www.facebook.com/ClosSYS/, and www.twitter.com/closys. The agencies reviewed these websites on October 22, 2020, and December 7, 2020.
The letter states that CloSYS Oral Spray, CloSYS Non-Irritating RINSE UN-flavored for ULTRA SENSITIVE Mouths, and CloSYS Non-Irritating RINSE Mildly Flavored for SENSITIVE Mouths are offered for sale with claims to mitigate, prevent, treat, diagnose, or cure COVID-19. The FDA determined these products are unapproved new drugs, violating section 505(a) of the FD&C Act (21 U.S.C. § 355(a)), and are misbranded drugs under section 502 (21 U.S.C. § 352). The introduction of these products into interstate commerce is prohibited by sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)).
The letter cites the public health emergency and national emergency declarations related to COVID-19 as context for urgent FDA action. The company is requested to immediately cease selling these unapproved and
ID · fea800b4-abe7-4a8f-8ef7-a2084b665885
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.